List of high-quality authors
Samsung Healthcare: Yi Shiwei resigned as president and director
Samsung Healthcare announced that the company's board of directors recently received the resignation report submitted by Mr. Yi Shiwei, director and president of the company. Mr. Yi Shiwei resigned as president and director of the company due to work transfer, and Mr. Yi Shiwei still served in the company after resigning as president and director. In order to ensure the smooth development of the company's related work, during the vacancy of the president, Mr. Cheng Zhihao, the rotating president of the company's electric energy division, will be elected as the president of the company's board of directors and appointed a new president as soon as possible in accordance with the relevant provisions of the "Company Law" and the "Articles of Association".
Jianxingyuan: JP-1366 tablets obtained the drug clinical trial approval notice].
Health Yuan announced that Livzon Pharmaceutical Research Institute (Livzon Pharmaceutical Research Institute), a wholly-owned subsidiary of Livzon Pharmaceutical Group Co., Ltd., a wholly-owned subsidiary of Livzon Group, received the "Notice of Approval for Drug Clinical Trials" (Notice No.: 2024LP00422) approved by the State Drug Administration, approving JP-1366 tablets to carry out clinical trials.
Borui data: net loss in 2023 is 10.5 billion yuan].
Borui Data announced the 2023 annual performance express report, and during the reporting period, the company achieved operating income of 12,447600,000 yuan, an increase of 6 year-on-year95%；Realized net profit attributable to owners of the parent company - 10,511570,000 yuan.
Haikan shares: SORA Wensheng** model has not had a direct effect on the company's short drama business
Haikan Co., Ltd. said on the interactive platform that AI technology can be widely used in business scenarios such as the creation, editing, and distribution of film and television content, helping to reduce costs and increase efficiency. The SORA Wensheng ** model released by Open AI has not yet opened the interface, and has not had a direct effect on the company's short drama business. The company will actively embrace the R&D and application of various AI technologies, and explore more application scenarios and business innovations.